NVS Stock Analysis: Buy, Sell, or Hold?
NVS - Novartis AG
$153.05
4.12 (2.77%)
▲
5d:
+0.98%
30d:
+0.85%
90d:
+3.35%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jul 16, 2026
22d
Get Alerted When NVS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NVS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$227.89
Based on 8.2% avg growth
INTRINSIC VALUE TODAY
$141.50
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: NVS is currently trading at $153.05, which is considered extended relative to its 30-day fair value range of $146.94 to $152.19. The stock's valuation (Forward PE: 15.0) is in line with its historical norms (15.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, NVS is in a downtrend. The price is approaching resistance at $154.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVS is in a downtrend. The price is approaching resistance at $154.71. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: NVS has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$146.94 -
$152.19
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($153.87)
Trading Range Analysis
30-Day Trading Range
$146.94 -
$152.19
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$146.60
Resistance Level
$154.71
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.99
Wall Street Target
$153.87
(+3.3%)
Revenue Growth (YoY)
-0.7%
Earnings Growth (YoY)
-9.3%
Profit Margin
23.9%
Valuation Discount vs History
-1.0% cheaper
PE vs Historical
15.0 vs 15.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.0%
(market-implied from PE analysis)
1-Year Target
$147.44
(-1%)
2-Year Target
$145.97
(-2%)
3-Year Target
$144.51
(-3%)
3-Yr Target (if PE normalizes)
(PE: 15→16)
$149.39
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 12.4%)
$307.22
(+106%)
Base:
(SPY PE: 15.0, Growth: 12.4%)
$211.49
(+42%)
Bear:
(PE: 12.7, Growth: 12.4%)
$179.77
(+21%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 21.04 | Current EPS (TTM): $6.99
Bull Case
$229.91
(+54%)
Analyst growth 42.1%, PE expands to 23.2
Base Case
$209.01
(+40%)
Market implied 42.1%, PE stable at 21.0
Bear Case
$100.01
(-33%)
Severe decline -20.0%, PE contracts to 17.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.0 to 15.5
Stabilization Target:
$153.96
(+3.4%)
PE Expansion Potential:
+3.4%
Share & Embed Analysis
Last updated: June 23, 2026 2:48 PM ET
Data refreshes hourly during market hours. Next update: 3:48 PM
Data refreshes hourly during market hours. Next update: 3:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1219 | 52 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 56 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$254 | 66 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$353 | 64 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$220 | 63 BUY |
